Clinical Trials Browser

Phase 2 × Uterine Cervical Neoplasms × Granulocyte Colony-Stimulating Factor × Clear all

NCT01266447 2019-08-08

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2 Completed

27 enrolled 11 charts

Uterine Cervical Neoplasms